We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
-4.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$44.1B
AUM Growth
+$629M
(+1.4%)
Cap. Flow
+$2.39B
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
11.51%
Holding
3,945
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halliburton
HAL
|
+$500M |
| 2 |
Archer Daniels Midland
ADM
|
+$463M |
| 3 |
Hewlett Packard
HPE
|
+$425M |
| 4 |
Gen Digital
GEN
|
+$379M |
| 5 |
WCC
WESCO International
WCC
|
+$269M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vistra
VST
|
+$598M |
| 2 |
ExxonMobil
XOM
|
+$504M |
| 3 |
Chevron
CVX
|
+$443M |
| 4 |
Occidental Petroleum
OXY
|
+$439M |
| 5 |
Cummins
CMI
|
+$414M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.1% |
| 2 | Technology | 16.69% |
| 3 | Energy | 13.9% |
| 4 | Industrials | 11.2% |
| 5 | Healthcare | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Altimmune
ALT
$539M
| $8.38K | ﹤0.01% |
1,260
-2,899
| -70% | -$21.4K |
|
1377
Arcus Biosciences
RCUS
$3.57B
| $8.3K | ﹤0.01% |
545
-1,034
| -65% | -$16.7K |
|
1378
Immunome
IMNM
$2.52B
| $7.99K | ﹤0.01% |
+660
| New | +$10.3K |
|
1379
CareDx
CDNA
$1.92B
| $7.91K | ﹤0.01% |
509
-1,189
| -70% | -$14.4K |
|
|
SAGE
1380
DELISTED
Sage Therapeutics
SAGE
| $7.61K | ﹤0.01% |
701
-1,125
| -62% | -$14.4K |
|
|
CDMO
1381
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $7.48K | ﹤0.01% |
1,048
-1,402
| -57% | -$10.7K |
|
1382
Summit Therapeutics
SMMT
$10.9B
| $7.36K | ﹤0.01% |
944
-2,085
| -69% | -$11.3K |
|
1383
Organon & Co
OGN
$3.55B
| $7.25K | ﹤0.01% |
350
+48
| +16% | +$954 |
|
1384
Relay Therapeutics
RLAY
$4.02B
| $7.19K | ﹤0.01% |
1,103
-1,054
| -49% | -$7.2K |
|
1385
AnaptysBio
ANAB
$1.6B
| $7.09K | ﹤0.01% |
283
-139
| -33% | -$3.24K |
|
1386
Ocugen
OCGN
$410M
| $7.03K | ﹤0.01% |
+4,534
| New | +$7.06K |
|
|
FIRY
1387
Firy Inc
FIRY
$127M
| $6.99K | ﹤0.01% |
974
-141
| -13% | -$917 |
|
1388
Regenxbio
RGNX
$623M
| $6.87K | ﹤0.01% |
587
-248
| -30% | -$3.86K |
|
1389
Teladoc Health
TDOC
$1.58B
| $6.81K | ﹤0.01% |
696
-1,544
| -69% | -$18.8K |
|
|
ETNB
1390
DELISTED
89bio
ETNB
| $6.54K | ﹤0.01% |
816
-1,330
| -62% | -$11.9K |
|
1391
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $6.44K | ﹤0.01% |
345
-315
| -48% | -$5.9K |
|
1392
Scholar Rock
SRRK
$5.71B
| $6.3K | ﹤0.01% |
756
-856
| -53% | -$10.5K |
|
1393
Olema Pharmaceuticals
OLMA
$1.02B
| $6.28K | ﹤0.01% |
580
-789
| -58% | -$8.56K |
|
1394
Stoke Therapeutics
STOK
$1.82B
| $6.13K | ﹤0.01% |
+454
| New | +$6.13K |
|
1395
Disc Medicine
IRON
$2.83B
| $6.13K | ﹤0.01% |
136
-341
| -71% | -$11.6K |
|
1396
Corbus Pharmaceuticals
CRBP
$170M
| $5.97K | ﹤0.01% |
+132
| New | +$5.55K |
|
1397
Editas Medicine
EDIT
$399M
| $5.71K | ﹤0.01% |
1,222
-2,526
| -67% | -$14.2K |
|
|
ATXS
1398
DELISTED
Astria Therapeutics
ATXS
| $5.58K | ﹤0.01% |
613
-119
| -16% | -$1.16K |
|
1399
Allogene Therapeutics
ALLO
$601M
| $5.53K | ﹤0.01% |
2,372
-1,285
| -35% | -$3.79K |
|
1400
MiMedx Group
MDXG
$626M
| $5.45K | ﹤0.01% |
786
-558
| -42% | -$3.92K |
|
Similar funds
SAM
Pacer Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, Pacer Advisors held 3,945 positions worth $44.1B, up 1.4% from $43.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $2.39B of net new capital in Q2 2024, opening 199 new positions and adding to 895 existing holdings. Its largest new stake was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Vistra, an estimated $598M trimmed.
- Pacer Advisors's largest Q2 2024 buy was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
- Pacer Advisors added most to Halliburton in Q2 2024, an estimated $500M increase.
- Pacer Advisors's biggest Q2 2024 reduction was Vistra, cutting an estimated $598M.
- Pacer Advisors fully exited American Eagle Outfitters in Q2 2024, selling an estimated $218M.
- Pacer Advisors's ten largest holdings make up 12% of its $44.1B portfolio in Q2 2024.
- Pacer Advisors opened 199 new positions and closed 190 in Q2 2024.
- Pacer Advisors's portfolio value rose 1.4% quarter-over-quarter to $44.1B.
Based on Pacer Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.